Miguel Escobar, MD
Hematology · Houston, TXNPI 1437177912
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $475,325 of the $766,806 with a category attached, or 62.0%. It is spread thinly across 25 manufacturers, the largest accounting for just 17.7%. Reporting peaked in 2023 at $177,027 and has fallen 57.8% since, to $74,625 in 2025. Among hematology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 488 payments — averaging $1571.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- HEMA Biologics, LLC$136K
- Sanofi$111K
- Novo Nordisk$103K
- Takeda Pharmaceuticals U.S.A., Inc.$97K
- CSL Behring$58K
- Novo Nordisk Health Care AG$56K
- plus $206K from 19 others
Across 185 payments — averaging $2364.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- HEMA Biologics, LLC$133K
- Novo Nordisk AS$102K
- Bayer$73K
- CSL Behring$34K
- Regeneron$24K
- Sanofi$24K
- plus $46K from 7 others
What the payments were for
- Consulting fees$475,32562%
- Speaking & faculty fees$171,08722%
- Travel & lodging$109,77914%
- Food & beverage$10,5951%
- Education$70%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| HEMA Biologics, LLC | 137 | $135,988 |
| Sanofi | 34 | $111,094 |
| Novo Nordisk | 51 | $102,720 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $97,405 |
| CSL Behring | 49 | $57,816 |
| Novo Nordisk Health Care AG | 16 | $56,044 |
| Biomarin Pharmaceutical Inc. | 43 | $40,409 |
| Genentech USA, Inc. | 27 | $31,305 |
| Sanofi US Services Inc. | 2 | $22,914 |
| Sanofi-aventis U.S. LLC | 7 | $21,992 |
| Pfizer | 13 | $16,993 |
| Bioverativ Therapeutics Inc. | 11 | $15,155 |
| Bayer | 16 | $11,258 |
| Novo Nordisk AS | 6 | $10,366 |
| Shire North American Group Inc | 5 | $7,263 |
| Genentech, Inc. | 3 | $6,600 |
| Kedrion Biopharma Inc. | 4 | $6,000 |
| Biocryst Pharmaceuticals, Inc. | 1 | $5,559 |
| Regeneron | 2 | $4,746 |
| F. Hoffmann-la Roche AG | 2 | $2,458 |
| Samsung Bioepis Co., Ltd. | 1 | $2,040 |
| Eagle Pharmaceuticals, Inc. | 1 | $400 |
| Spark Therapeutics, Inc. | 2 | $132 |
| Eisai Inc. | 5 | $110 |
| Grifols USA, LLC | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$766,806 in reported general payments places this provider in the 95th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Warfarin Sodium | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Other hematology in Houston
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Swaminathan IyerHouston$50K
- Jing YeHouston$34K
- Senthil SukumarHouston$31K
- Sa WangHouston$27K
- Uday PopatHouston$25K
- Rashmi Kanagal ShamannaHouston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.